Biotech company BioMarin Pharmaceutical (NASDAQ: BMRN) will be announcing earnings results this Monday after market close. Here’s what you need to know.

BioMarin Pharmaceutical beat analysts’ revenue expectations by 8.4% last quarter, reporting revenues of $825.4 million, up 15.9% year on year. It was an exceptional quarter for the company, with a beat of analysts’ EPS estimates and a solid beat of analysts’ revenue estimates.

Is BioMarin Pharmaceutical a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting BioMarin Pharmaceutical’s revenue to grow 4.4% year on year to $778.3 million, slowing from the 28.3% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.32 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. BioMarin Pharmaceutical has missed Wall Street’s revenue estimates twice over the last two years.

With BioMarin Pharmaceutical being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unravel for biotechnology stocks. However, there has been positive investor sentiment in the segment, with share prices up 7.7% on average over the last month. BioMarin Pharmaceutical is up 2.1% during the same time and is heading into earnings with an average analyst price target of $94.80 (compared to the current share price of $54.99).

Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.